The role of CD133 expression of cancer stem cells on radiotherapy response in early stage glottic cancers
Purpose To investigate the relationship between CD133 positivity and radiotherapy (RT) response in early stage glottic laryngeal cancers. Methods Thirty seven patients with early-stage glottic laryngeal carcinoma who were treated with primary RT were evaluated. Patients with regular follow-up of at...
Gespeichert in:
| Veröffentlicht in: | European archives of oto-rhino-laryngology 2020-11, Vol.277 (11), p.3121-3126 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3126 |
|---|---|
| container_issue | 11 |
| container_start_page | 3121 |
| container_title | European archives of oto-rhino-laryngology |
| container_volume | 277 |
| creator | Gülmez, Emrah Yüce, Imdat Gündoğ, Mete Canöz, Özlem Kökoğlu, Kerem Vural, Alperen Çağlı, Sedat |
| description | Purpose
To investigate the relationship between CD133 positivity and radiotherapy (RT) response in early stage glottic laryngeal cancers.
Methods
Thirty seven patients with early-stage glottic laryngeal carcinoma who were treated with primary RT were evaluated. Patients with regular follow-up of at least 3 years were included in the study. Patients who had previously received chemotherapy for laryngeal surgery or underwent surgery were excluded. The patients were divided into two groups as recurrent and non-recurrent. These two groups were compared in terms of CD133 expression by immunohistochemical method.
Results
There were 37 patients in the study
.
Ten patients had recurrence and seven (70%) had CD133 positive and three had CD133 negative. Of 27 patients who had no recurrence, 16 (59%) had CD133 positive and 11 (41%) had CD133 negative. 7 (70%) of ten patients with recurrence were found to be positive for CD133; There was no statistically significant difference between recurrent and non-recurrent patient groups in terms of CD133 positivity (
p
> 0.05). There was no correlation between the final CD133 score and recurrence status as well (
p
> 0.05).
Conclusion
There was no relationship between radiotherapy response and CD133 staining in early-stage glottic laryngeal cancers. It is the largest study about CD133 and RT sensitivity in early stage glottic carcinomas. |
| doi_str_mv | 10.1007/s00405-020-06106-4 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2411537268</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2411537268</sourcerecordid><originalsourceid>FETCH-LOGICAL-c347t-6924254cd016c95353f32fc1c09837ba2fc9fc850dc62acd50deeeaa32b6325c3</originalsourceid><addsrcrecordid>eNp9kMtOwzAQRS0EoqXwAyyQl2wC41ceS1SeUiU2ZW25zqRNlcTBTiT697i0sGTl0fjM1cwh5JrBHQPI7gOABJUAhwRSBmkiT8iUSSETmfH0lEyhEFkiZZZNyEUIWwBQshDnZCK4YgXkMCX1coPUuwapq-j8kQlB8av3GELtun3Pms6ip2HAllpsmkBj35uydsMGvel3NMK96wLSuqNofLOLsFkjXTduGGp7TAiX5KwyTcCr4zsjH89Py_lrsnh_eZs_LBIrZDYkacElV9KWwFJbKKFEJXhlmYUiF9nKxLqobK6gtCk3towFIhoj-CqNZ1kxI7eH3N67zxHDoNs67Dc3HboxaC4ZUyIKyiPKD6j1LgSPle593Rq_0wz0XrE-KNZRsf5RrGUcujnmj6sWy7-RX6cREAcgxK9ujV5v3ei7ePN_sd_vwocK</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2411537268</pqid></control><display><type>article</type><title>The role of CD133 expression of cancer stem cells on radiotherapy response in early stage glottic cancers</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Gülmez, Emrah ; Yüce, Imdat ; Gündoğ, Mete ; Canöz, Özlem ; Kökoğlu, Kerem ; Vural, Alperen ; Çağlı, Sedat</creator><creatorcontrib>Gülmez, Emrah ; Yüce, Imdat ; Gündoğ, Mete ; Canöz, Özlem ; Kökoğlu, Kerem ; Vural, Alperen ; Çağlı, Sedat</creatorcontrib><description>Purpose
To investigate the relationship between CD133 positivity and radiotherapy (RT) response in early stage glottic laryngeal cancers.
Methods
Thirty seven patients with early-stage glottic laryngeal carcinoma who were treated with primary RT were evaluated. Patients with regular follow-up of at least 3 years were included in the study. Patients who had previously received chemotherapy for laryngeal surgery or underwent surgery were excluded. The patients were divided into two groups as recurrent and non-recurrent. These two groups were compared in terms of CD133 expression by immunohistochemical method.
Results
There were 37 patients in the study
.
Ten patients had recurrence and seven (70%) had CD133 positive and three had CD133 negative. Of 27 patients who had no recurrence, 16 (59%) had CD133 positive and 11 (41%) had CD133 negative. 7 (70%) of ten patients with recurrence were found to be positive for CD133; There was no statistically significant difference between recurrent and non-recurrent patient groups in terms of CD133 positivity (
p
> 0.05). There was no correlation between the final CD133 score and recurrence status as well (
p
> 0.05).
Conclusion
There was no relationship between radiotherapy response and CD133 staining in early-stage glottic laryngeal cancers. It is the largest study about CD133 and RT sensitivity in early stage glottic carcinomas.</description><identifier>ISSN: 0937-4477</identifier><identifier>EISSN: 1434-4726</identifier><identifier>DOI: 10.1007/s00405-020-06106-4</identifier><identifier>PMID: 32519080</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Carcinoma, Squamous Cell - pathology ; Glottis - pathology ; Head and Neck Surgery ; Humans ; Laryngeal Neoplasms - pathology ; Laryngeal Neoplasms - radiotherapy ; Laryngectomy ; Laryngology ; Medicine ; Medicine & Public Health ; Neoplasm Recurrence, Local - pathology ; Neoplasm Staging ; Neoplastic Stem Cells ; Neurosurgery ; Otorhinolaryngology ; Retrospective Studies</subject><ispartof>European archives of oto-rhino-laryngology, 2020-11, Vol.277 (11), p.3121-3126</ispartof><rights>Springer-Verlag GmbH Germany, part of Springer Nature 2020</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c347t-6924254cd016c95353f32fc1c09837ba2fc9fc850dc62acd50deeeaa32b6325c3</citedby><cites>FETCH-LOGICAL-c347t-6924254cd016c95353f32fc1c09837ba2fc9fc850dc62acd50deeeaa32b6325c3</cites><orcidid>0000-0003-1749-7095</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00405-020-06106-4$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00405-020-06106-4$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32519080$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gülmez, Emrah</creatorcontrib><creatorcontrib>Yüce, Imdat</creatorcontrib><creatorcontrib>Gündoğ, Mete</creatorcontrib><creatorcontrib>Canöz, Özlem</creatorcontrib><creatorcontrib>Kökoğlu, Kerem</creatorcontrib><creatorcontrib>Vural, Alperen</creatorcontrib><creatorcontrib>Çağlı, Sedat</creatorcontrib><title>The role of CD133 expression of cancer stem cells on radiotherapy response in early stage glottic cancers</title><title>European archives of oto-rhino-laryngology</title><addtitle>Eur Arch Otorhinolaryngol</addtitle><addtitle>Eur Arch Otorhinolaryngol</addtitle><description>Purpose
To investigate the relationship between CD133 positivity and radiotherapy (RT) response in early stage glottic laryngeal cancers.
Methods
Thirty seven patients with early-stage glottic laryngeal carcinoma who were treated with primary RT were evaluated. Patients with regular follow-up of at least 3 years were included in the study. Patients who had previously received chemotherapy for laryngeal surgery or underwent surgery were excluded. The patients were divided into two groups as recurrent and non-recurrent. These two groups were compared in terms of CD133 expression by immunohistochemical method.
Results
There were 37 patients in the study
.
Ten patients had recurrence and seven (70%) had CD133 positive and three had CD133 negative. Of 27 patients who had no recurrence, 16 (59%) had CD133 positive and 11 (41%) had CD133 negative. 7 (70%) of ten patients with recurrence were found to be positive for CD133; There was no statistically significant difference between recurrent and non-recurrent patient groups in terms of CD133 positivity (
p
> 0.05). There was no correlation between the final CD133 score and recurrence status as well (
p
> 0.05).
Conclusion
There was no relationship between radiotherapy response and CD133 staining in early-stage glottic laryngeal cancers. It is the largest study about CD133 and RT sensitivity in early stage glottic carcinomas.</description><subject>Carcinoma, Squamous Cell - pathology</subject><subject>Glottis - pathology</subject><subject>Head and Neck Surgery</subject><subject>Humans</subject><subject>Laryngeal Neoplasms - pathology</subject><subject>Laryngeal Neoplasms - radiotherapy</subject><subject>Laryngectomy</subject><subject>Laryngology</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Neoplasm Recurrence, Local - pathology</subject><subject>Neoplasm Staging</subject><subject>Neoplastic Stem Cells</subject><subject>Neurosurgery</subject><subject>Otorhinolaryngology</subject><subject>Retrospective Studies</subject><issn>0937-4477</issn><issn>1434-4726</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMtOwzAQRS0EoqXwAyyQl2wC41ceS1SeUiU2ZW25zqRNlcTBTiT697i0sGTl0fjM1cwh5JrBHQPI7gOABJUAhwRSBmkiT8iUSSETmfH0lEyhEFkiZZZNyEUIWwBQshDnZCK4YgXkMCX1coPUuwapq-j8kQlB8av3GELtun3Pms6ip2HAllpsmkBj35uydsMGvel3NMK96wLSuqNofLOLsFkjXTduGGp7TAiX5KwyTcCr4zsjH89Py_lrsnh_eZs_LBIrZDYkacElV9KWwFJbKKFEJXhlmYUiF9nKxLqobK6gtCk3towFIhoj-CqNZ1kxI7eH3N67zxHDoNs67Dc3HboxaC4ZUyIKyiPKD6j1LgSPle593Rq_0wz0XrE-KNZRsf5RrGUcujnmj6sWy7-RX6cREAcgxK9ujV5v3ei7ePN_sd_vwocK</recordid><startdate>20201101</startdate><enddate>20201101</enddate><creator>Gülmez, Emrah</creator><creator>Yüce, Imdat</creator><creator>Gündoğ, Mete</creator><creator>Canöz, Özlem</creator><creator>Kökoğlu, Kerem</creator><creator>Vural, Alperen</creator><creator>Çağlı, Sedat</creator><general>Springer Berlin Heidelberg</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-1749-7095</orcidid></search><sort><creationdate>20201101</creationdate><title>The role of CD133 expression of cancer stem cells on radiotherapy response in early stage glottic cancers</title><author>Gülmez, Emrah ; Yüce, Imdat ; Gündoğ, Mete ; Canöz, Özlem ; Kökoğlu, Kerem ; Vural, Alperen ; Çağlı, Sedat</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c347t-6924254cd016c95353f32fc1c09837ba2fc9fc850dc62acd50deeeaa32b6325c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Carcinoma, Squamous Cell - pathology</topic><topic>Glottis - pathology</topic><topic>Head and Neck Surgery</topic><topic>Humans</topic><topic>Laryngeal Neoplasms - pathology</topic><topic>Laryngeal Neoplasms - radiotherapy</topic><topic>Laryngectomy</topic><topic>Laryngology</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Neoplasm Recurrence, Local - pathology</topic><topic>Neoplasm Staging</topic><topic>Neoplastic Stem Cells</topic><topic>Neurosurgery</topic><topic>Otorhinolaryngology</topic><topic>Retrospective Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gülmez, Emrah</creatorcontrib><creatorcontrib>Yüce, Imdat</creatorcontrib><creatorcontrib>Gündoğ, Mete</creatorcontrib><creatorcontrib>Canöz, Özlem</creatorcontrib><creatorcontrib>Kökoğlu, Kerem</creatorcontrib><creatorcontrib>Vural, Alperen</creatorcontrib><creatorcontrib>Çağlı, Sedat</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European archives of oto-rhino-laryngology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gülmez, Emrah</au><au>Yüce, Imdat</au><au>Gündoğ, Mete</au><au>Canöz, Özlem</au><au>Kökoğlu, Kerem</au><au>Vural, Alperen</au><au>Çağlı, Sedat</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The role of CD133 expression of cancer stem cells on radiotherapy response in early stage glottic cancers</atitle><jtitle>European archives of oto-rhino-laryngology</jtitle><stitle>Eur Arch Otorhinolaryngol</stitle><addtitle>Eur Arch Otorhinolaryngol</addtitle><date>2020-11-01</date><risdate>2020</risdate><volume>277</volume><issue>11</issue><spage>3121</spage><epage>3126</epage><pages>3121-3126</pages><issn>0937-4477</issn><eissn>1434-4726</eissn><abstract>Purpose
To investigate the relationship between CD133 positivity and radiotherapy (RT) response in early stage glottic laryngeal cancers.
Methods
Thirty seven patients with early-stage glottic laryngeal carcinoma who were treated with primary RT were evaluated. Patients with regular follow-up of at least 3 years were included in the study. Patients who had previously received chemotherapy for laryngeal surgery or underwent surgery were excluded. The patients were divided into two groups as recurrent and non-recurrent. These two groups were compared in terms of CD133 expression by immunohistochemical method.
Results
There were 37 patients in the study
.
Ten patients had recurrence and seven (70%) had CD133 positive and three had CD133 negative. Of 27 patients who had no recurrence, 16 (59%) had CD133 positive and 11 (41%) had CD133 negative. 7 (70%) of ten patients with recurrence were found to be positive for CD133; There was no statistically significant difference between recurrent and non-recurrent patient groups in terms of CD133 positivity (
p
> 0.05). There was no correlation between the final CD133 score and recurrence status as well (
p
> 0.05).
Conclusion
There was no relationship between radiotherapy response and CD133 staining in early-stage glottic laryngeal cancers. It is the largest study about CD133 and RT sensitivity in early stage glottic carcinomas.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>32519080</pmid><doi>10.1007/s00405-020-06106-4</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0003-1749-7095</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0937-4477 |
| ispartof | European archives of oto-rhino-laryngology, 2020-11, Vol.277 (11), p.3121-3126 |
| issn | 0937-4477 1434-4726 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2411537268 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Carcinoma, Squamous Cell - pathology Glottis - pathology Head and Neck Surgery Humans Laryngeal Neoplasms - pathology Laryngeal Neoplasms - radiotherapy Laryngectomy Laryngology Medicine Medicine & Public Health Neoplasm Recurrence, Local - pathology Neoplasm Staging Neoplastic Stem Cells Neurosurgery Otorhinolaryngology Retrospective Studies |
| title | The role of CD133 expression of cancer stem cells on radiotherapy response in early stage glottic cancers |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T06%3A32%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20role%20of%20CD133%20expression%20of%20cancer%20stem%20cells%20on%20radiotherapy%20response%20in%20early%20stage%20glottic%20cancers&rft.jtitle=European%20archives%20of%20oto-rhino-laryngology&rft.au=G%C3%BClmez,%20Emrah&rft.date=2020-11-01&rft.volume=277&rft.issue=11&rft.spage=3121&rft.epage=3126&rft.pages=3121-3126&rft.issn=0937-4477&rft.eissn=1434-4726&rft_id=info:doi/10.1007/s00405-020-06106-4&rft_dat=%3Cproquest_cross%3E2411537268%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2411537268&rft_id=info:pmid/32519080&rfr_iscdi=true |